<DOC>
	<DOCNO>NCT02135276</DOCNO>
	<brief_summary>This multi-center , open-label clinical study ass single-dose PK eravacycline subject renal impairment healthy subject conduct approximately 2 site United States . This study include 21-day Screening Period , 5-day Treatment Period , End Study Visit occur approximately 2 week ( ±2 day ) study drug administration . Approximately 12 subject enrol : 6 subject ESRD 6 healthy subject normal renal function . Healthy subject match renally impaired subject gender , age , body mass index ( BMI ) . All subject administer single IV dose eravacycline ( 1.5 mg/kg ) .</brief_summary>
	<brief_title>A Phase 1 , Open-Label Study Assess Single-Dose Pharmacokinetics Eravacycline Subjects With End Stage Renal Disease Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<criteria>1 . Male female subject age 18 year Screening ; 2 . Eligible female subject childbearing potential nonsterilized male sexual partner must agree use 2 medically accept , effective method birth control ( eg , hormonal contraceptive , barrier contraceptive additional spermicide , intrauterine device ) begin &gt; 30 day prior study drug administration continue 7 day end study . Female subject postmenopausal must postmenopausal &gt; 1 year wish use contraceptive . If postmenopausal status questionable , subject 's follicle stimulate hormone level must check must elevate consistent postmenopausal level ( ie , &gt; 40 IU/L ) ; otherwise subject must agree use contraceptive list ; 3 . Male subject sexual partner childbearing potential must agree use barrier contraceptive time study drug administration 7 day end study ; 4 . Female subject childbearing potential ( include female questionable postmenopausal status ) must negative pregnancy test prior dose ( Screening Day 1 ) ; 5 . Has body mass index 17 kg/m2 40 kg/m2 , inclusive ; 6 . Has negative alcohol illicit drug screen ; 7 . Has negative screen Human Immunodeficiency Virus ; 8 . Is able understand comply study procedure give write informed consent accord institutional regulatory guideline ; Subjects ESRD renal impairment : 9 . Has positive diagnosis ESRD maintain hemodialysis treatment 3 time week least 3 month minimum Kt/V 1.2 ; 10 . Is otherwise consider healthy except abnormality consistent underlie ESRD determine past medical history , physical examination , vital sign , laboratory test Screening ; Healthy subject without renal impairment : 11 . Must good health determine screen medical history , physical examination , vital sign , blood chemistry , hematology , glucose , coagulation performance Screening ; 12 . Has negative screen hepatitis B ( HBV ) hepatitis C ( HCV ) ; 13 . Should match subject renal impairment gender , age , BMI . 1 . Female subject pregnant , breastfeeding , plan become pregnant course study ; 2 . Has history current evidence clinically significant hematological , hepatic , endocrine , pulmonary , gastrointestinal , cardiovascular , neurological , psychiatric disease may pose significant safety risk diminish subject 's ability undergo study procedures assessment ; 3 . Use another investigational drug device within 30 day prior receive eravacycline ( TP434 ) , within least 5 halflives previous investigational drug , whichever longer ; 4 . Has history alcoholism drug abuse within 6 month prior dose ; 5 . Has urinary incontinence ; 6 . Has typical weekly alcohol consumption 14 alcoholic drink . One drink define 1 glass beer ( approximately 10 oz 12 oz ) 1 ( 12 oz ) beer , 1 glass wine ( approximately 4 oz 5 oz ) , 1 glass distil spirit ( hard liquor ) contain 1 oz liquor ( 1 oz liquid approximately 30 mL ) ; 7 . Use alcohol within 48 hour prior admission completion final PK draw Day 5 ; 8 . Has major surgical procedure within 3 month prior administration study drug ; 9 . Has know allergy tetracycline antibiotic related compound , history multiple adverse drug allergy origin ; 10 . Has inadequate venous access ; 11 . Donated &gt; 500 mL blood within 2 month prior Screening ; 12 . Is member clinical site personnel directly affiliate study ; 13 . Has poor mental function reason expect subject difficulty comply requirement study judgment investigator ; 14 . Has surgical medical condition might significantly alter absorption , distribution , excretion drug ; 15 . Fails comply protocol requirement , whose participation study would unsuitable subject , determined investigator ; 16 . Clinically significant abnormal electrocardiogram ( ECGs ) ( QTcF &gt; 500 msec ) ; 17 . Has clinically significant abnormal laboratory value ( ) , consistent stage 5 chronic kidney disease . Aspartate aminotransferase alanine aminotransferase &gt; 1.5 × upper limit reference range total bilirubin &gt; 1.5 × upper limit reference range . A single repeat allow eligibility determination ; 18 . Unwillingness refrain liquid food contain grapefruit , cranberry , caffeine , xanthines 96 hour prior admission completion final PK draw Day 5 ; 19 . Unwillingness refrain eat food contain poppy seed 48 hour admission completion final PK draw Day 5 ; 20 . Unwillingness abstain unaccustomed strenuous exercise contact sport least 72 hour prior Screening Visit 72 hour prior admission Day 1 discharge study ; Subjects ESRD renal impairment : 21 . Has active HCV HBV receive antiviral therapy ( either prescribe herbal ) ; 22 . Has fluctuate rapidly deteriorate renal function indicate clinical and/or laboratory sign renal impairment ; 23 . Has sign active infection ; 24 . Takes herbal concomitant medication within 7 day , 5 halflives ( know ) , whichever longer , prior dose within 24 hour dose , exclude hormonal contraceptive ; Subjects without renal impairment : 25 . Has systolic blood pressure outside range 90160 mmHg , diastolic blood pressure outside range 45100 mmHg , heart rate outside range 50 100 bpm female subject 45100 bpm male subject ; 26 . Has history Gilbert 's disease ; 27 . Takes concomitant medication , either prescribed counter . This include prescription nonprescription medication , include vitamin herbal medication , within 7 day , 5 halflives ( know ) , whichever longer , prior dose within 24 hour dose , exclude hormonal contraceptive . The use acetaminophen , naproxen , ibuprofen permit except within 24 hour prior dose .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>